Alvotech turns to a CDMO's 40,000-liter Syracuse facility for biosimilar drug substance as it expands its manufacturing network.
|Articles|April 9, 2008
Shobha Parthasarathi Joins NC Biotech Center as Technology Development Director
Author(s)BioPharm International Editors
Shobha Parthasarathi, PhD, has joined the North Carolina Biotechnology Center (Research Triangle Park, NC) as technology development director in the Business and Technology Development unit.
Advertisement
Shobha Parthasarathi, PhD, has joined the North Carolina Biotechnology Center (Research Triangle Park, NC) as technology development director in the Business and Technology Development unit. Before joining the Biotechnology Center, Parthasarathi was a senior researcher and manager at Millennium Pharmaceuticals (Cambridge, MA).
North Carolina Biotechnology Center's
Advertisement
Related to this article
New data and partnerships are advancing brain-penetrant enzyme therapy, targeted antibodies, flexible obesity dosing, and frontline lymphoma treatment strategies.
Topline phase 3 data show epcoritamab plus R-CHOP reduced the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.
Part 2 of the VK2735 maintenance study tests whether daily or weekly oral tablets can hold weight loss first achieved with weekly subcutaneous injections.
CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.
AL050 aims to treat GBA1-driven Parkinson disease by delivering a GCase enzyme across the blood-brain barrier.
Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Advertisement
Advertisement